Psilocybin Microdosing for Anxiety Relief in Young Adults: A Comparative Review of Emerging Evidence

Microdosing psilocybin—taking very small, sub-hallucinogenic doses—may help relieve anxiety in young adults. A systematic review of studies published between 2014 and 2024 found that microdosing is associated with improved mood, reduced anxiety symptoms, and enhanced emotional resilience and mental well-being. The compound appears to work by modulating serotonin receptors, promoting neural plasticity, and improving connectivity in brain regions involved in emotional regulation. Short-term benefits include increased focus and cognitive flexibility; long-term effects may involve sustained anxiety reduction and better overall mental health. However, variability in study designs and dosing regimens underscores the need for standardized protocols and further research on long-term safety and efficacy.

Study at a glance

Abstract

Background Anxiety disorders are increasingly prevalent among young adults. Traditional treatment options often fall short, and many patients live with treatment-resistant anxiety. Psilocybin is a psychedelic compound that has gained attention for its therapeutic potential against anxiety when used in microdoses. Objective This review aims to evaluate the emerging evidence on psilocybin microdosing as a potential intervention for anxiety relief in young adults. It examines psilocybin microdosing efficacy, safety, and underlying mechanism of action. Methods A systematic search was conducted across three major databases: PubMed, PsycINFO, and CINAH. Keywords were selected related to psilocybin microdosing and anxiety in young adults. Inclusion criteria focused on peer-reviewed studies published in English from 2014 to 2024, encompassing human participants aged 18-35 years. Data were synthesised narratively with thematic analysis of anxiety-related outcomes across studies. Tabular comparisons to highlight psilocybin microdosing’s relative efficacy, limitations, and methodological variations were used. Findings The findings suggest that psilocybin microdosing is associated with improved mood and reduced anxiety symptoms. It also enhances emotional resilience and mental well-being. Microdosing can modulate serotonin receptors, promote neural plasticity, and improve connectivity in certain brain regions implicated in emotional regulation. Short-term benefits include increased focus and cognitive flexibility, while long-term effects may involve sustained reductions in anxiety and improved overall mental well-being. Conclusion Psilocybin microdosing presents a promising alternative for managing anxiety in young adults for those who are resistant to traditional therapies. However, the variability in study designs and dosing regimens highlights the need for further research to establish standardised protocols and assess long-term safety and efficacy.